相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
Guadalupe Garcia-Tsao et al.
JOURNAL OF HEPATOLOGY (2020)
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo
Catherine T. Frenette et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2019)
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
Mitchell Shiffman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2019)
Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States
George Cholankeril et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau et al.
HEPATOLOGY (2018)
Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C
Ezequiel Mauro et al.
HEPATOLOGY (2018)
Sofosbuvir, Velpatasvir , and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
Maria G. Cardona-Gonzalez et al.
HEPATOLOGY COMMUNICATIONS (2018)
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
David Goldberg et al.
GASTROENTEROLOGY (2017)
Safety and Efficacy of Current Direct-Acting Antiviral Regimens in Kidney and Liver Transplant Recipients With Hepatitis C: Results From the HCV-TARGET Study
Varun Saxena et al.
HEPATOLOGY (2017)
Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States
Giorgia L. Garrett et al.
JAMA DERMATOLOGY (2017)
Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication
Emma Whitcomb et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
The Current State of Liver Transplantation in the United States Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council
S. A. Fayek et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment
Shahid Habib et al.
GASTROENTEROLOGY RESEARCH (2015)
Apoptosis as a Mechanism for Liver Disease Progression
Maria Eugenia Guicciardi et al.
SEMINARS IN LIVER DISEASE (2010)
Clinical, Virologic, Histologic, and Biochemical Outcomes After Successful HCV Therapy: A 5-Year Follow-up of 150 Patients
Sarah L. George et al.
HEPATOLOGY (2009)
The Natural History of Hepatitis C Cirrhosis After Liver Transplantation
Roberto J. Firpi et al.
LIVER TRANSPLANTATION (2009)
Hepatitis C Virus Therapy in Liver Transplant Recipients: Response Predictors, Effect on Fibrosis Progression, and Importance of the Initial Stage of Fibrosis
Bruno Roche et al.
LIVER TRANSPLANTATION (2008)
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
Paul J. Pockros et al.
HEPATOLOGY (2007)
First-in-class pan caspase inhibitor developed for the treatment of liver disease
SD Linton et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
MF Abdelmalek et al.
LIVER TRANSPLANTATION (2004)
Some design issues in trials of microbicides for the prevention of HIV infection
TR Fleming et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
RJ Firpi et al.
LIVER TRANSPLANTATION (2002)
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
T Poynard et al.
GASTROENTEROLOGY (2002)
分享论文
